Collegium Pharmaceutical (COLL) Cash from Investing Activities Growth (3y) (2018 - 2026)
Powered by 
Analysis
Collegium Pharmaceutical (COLL) Cash from Investing Activities Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -47.89% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 27.70% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -91.04% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 33.61% |
| 10 | Collegium Pharmaceutical | 753.09 Mn | 603.77 Mn | 110.29 Mn | -129.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -129.25% |
| Mar 31, 2026 | 124.03% |
| Dec 31, 2025 | -177.42% |
| Sep 30, 2025 | -548.85% |
| Jun 30, 2025 | -84.92% |
| Mar 31, 2025 | 74.33% |
| Dec 31, 2024 | -183.72% |
| Sep 30, 2024 | -866.22% |
| Jun 30, 2024 | -130.74% |
| Mar 31, 2024 | -248.58% |
| Dec 31, 2023 | -156.86% |
| Sep 30, 2023 | -16.73% |
| Jun 30, 2023 | -165.03% |
| Mar 31, 2023 | 92.18% |
| Dec 31, 2022 | -1.88% |
| Sep 30, 2022 | 56.27% |
| Jun 30, 2022 | 19.23% |
| Mar 31, 2022 | -456.33% |
| Dec 31, 2021 | 33.77% |
| Sep 30, 2021 | 53.34% |